Microbot Medical (NASDAQ:MBOT) Posts Earnings Results, Misses Expectations By $0.01 EPS
Microbot Medical (NASDAQ:MBOT) reported a quarterly earnings per share of ($0.07), missing the consensus estimate by $0.01. The stock traded at $2.12 with a market cap of $142.37 million. Analysts have mixed ratings: one Buy, one Hold, and one Sell. Institutional investors own 16.30% of the company. Microbot Medical develops robotic endoluminal surgery devices, including the LIBERTY system.
Microbot Medical (NASDAQ:MBOT - Get Free Report) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01), Zacks reports.
Get Microbot Medical alerts:
Microbot Medical Price Performance
- Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs
Shares of Microbot Medical stock traded up $0.03 during trading on Wednesday, hitting $2.12. The stock had a trading volume of 1,402,659 shares, compared to its average volume of 3,445,473. Microbot Medical has a 12 month low of $0.89 and a 12 month high of $4.67. The stock has a market cap of $142.37 million, a PE ratio of -3.66 and a beta of 1.22. The firm's fifty day simple moving average is $2.93 and its 200-day simple moving average is $2.82.
Wall Street Analyst Weigh In
MBOT has been the topic of several research analyst reports. Zacks Research lowered shares of Microbot Medical from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 21st. HC Wainwright reissued a "buy" rating and issued a $12.00 price objective on shares of Microbot Medical in a report on Wednesday, October 15th. Wall Street Zen lowered shares of Microbot Medical from a "hold" rating to a "sell" rating in a research report on Saturday, October 25th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Microbot Medical in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $12.00.
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
View Our Latest Stock Analysis on Microbot Medical
Institutional Trading of Microbot Medical
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in shares of Microbot Medical by 14.3% in the third quarter. Vanguard Group Inc. now owns 2,343,561 shares of the biotechnology company's stock worth $7,148,000 after purchasing an additional 292,923 shares during the last quarter. Envestnet Asset Management Inc. acquired a new position in shares of Microbot Medical during the third quarter valued at approximately $98,000. XTX Topco Ltd acquired a new position in shares of Microbot Medical during the 2nd quarter worth approximately $43,000. American Century Companies Inc. acquired a new position in shares of Microbot Medical during the 2nd quarter valued at about $32,000. Finally, Geode Capital Management LLC boosted its holdings in Microbot Medical by 24.7% in the 2nd quarter. Geode Capital Management LLC now owns 395,039 shares of the biotechnology company's stock valued at $996,000 after purchasing an additional 78,121 shares during the last quarter. Institutional investors own 16.30% of the company's stock.
Microbot Medical Company Profile
(Get Free Report)Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
See Also
- Five stocks we like better than Microbot Medical
- Why Are These Companies Considered Blue Chips?
- Rare Earth Stocks: The Truce That Isn't a Truce
- Industrial Products Stocks Investing
- Carving Up Profits: 3 Food Stocks on the Thanksgiving Table
- How to Effectively Use the MarketBeat Ratings Screener
- C3.ai's Reset: Why New Leadership Could Spark a Turnaround
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Microbot Medical Right Now?
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
